4F-MDMB-BINACA

4F-MDMB-BINACA (also known as 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.[1] It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug. 4F-MDMB-BINACA is an agonist of the CB1 receptor, though it is unclear whether it is selective for this target.[2] In December 2019, the UNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II.[3]

4F-MDMB-BINACA
Legal status
Legal status
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC19H26FN3O3
Molar mass363.433 g·mol−1
3D model (JSmol)

See also

References

  1. Krotulski, Alex J.; Mohr, Amanda L. A.; Kacinko, Sherri L.; Fogarty, Melissa F.; Shuda, Sarah A.; Diamond, Francis X.; Kinney, William A.; Menendez, M. J.; Logan, Barry K. (September 2019). "4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework". Journal of Forensic Sciences. 64 (5): 1451–1461. doi:10.1111/1556-4029.14101. ISSN 1556-4029. PMID 31260580.
  2. "4F-MDMB-BINACA(4F-MDMB-BUTINACA)" (PDF).
  3. "December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.